Skip to main content

What the FDA labels say about taking them together

Lenacapavir and nevirapine

Lenacapavir's FDA label of August 27, 2026 names nevirapine in its drug interactions section; the nevirapine label PlainMeds reads does not name lenacapavir.

Check it at the source: the lenacapavir FDA label on DailyMed (effective August 27, 2026, Gilead Sciences, Inc.); the nevirapine FDA label on DailyMed (effective July 15, 2026, Mylan Pharmaceuticals Inc.).

What does the lenacapavir label say about nevirapine?

Lenacapavir label, drug interactions

Concomitant Drug Class/Drug Name: Antiretroviral Agents: atazanavir/cobicistat Drug-drug interaction study was conducted. atazanavir/ritonavir; Effect on Concentration ↑ = Increase, ↓ = Decrease.: ↑ lenacapavir (atazanavir/cobicistat, atazanavir/ritonavir); Clinical Comment: Concomitant administration of efavirenz, nevirapine, or tipranavir/ritonavir may result in loss of therapeutic effect and development of resistance.

Source: FDA drug label (Sunlenca), Gilead Sciences, Inc., effective August 27, 2026 (SPL set e5652804-29c4-40d7-aeb2-0142ed2a7b5b), via openFDA; the full label on DailyMed

What does the nevirapine label say about lenacapavir?

Nevirapine's label (effective July 15, 2026) does not name lenacapavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Nevirapine), Mylan Pharmaceuticals Inc., effective July 15, 2026 (SPL set c6e93829-7024-48f6-8023-da6ff27dfc0a), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Lenacapavir generic labelers
6Nevirapine generic labelers
LenacapavirNevirapine
Labeled forHIVHIV
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.147 per tablet 200 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?